Background: We herein report the long-term results of an allogeneic reduced-intensity conditioning (allo-RIC) protocol used in 21 consecutive patients (16 males, median age 56 years, 71% in complete remission) diagnosed with mantle cell lymphoma (MCL). Methods: The allo-RIC consisted of fludarabine plus melphalan and peripheral blood hematopoietic stem cells (PBSCs) from human leukocyte antigen (HLA)-identical siblings were used in all cases. Median CD34þ infused cells was 5.8 Â 10 6 /kg. All patients engrafted promptly. Results: Early toxicity included mild/moderate mucositis (43%), febrile neutropenia (33%) and bacterial infections (19%). With a median follow up of 48 months, four deaths were reported, all due to infections and/or graft-versus-host disease (GVHD), yielding a 3-year cumulative incidence of nonrelapse mortality of 19.5%. Grade IIIIV acute GVHD occurred in 15% and chronic GVHD in 78%, being extensive in 39%. The 5-year progression-free survival (PFS) and overall survival (OS) were both 80% (95% CI: 6397%). Age was the only possible prognostic factor for OS, which was 43% for those aged more than 60 years and 100% for those younger (p < 0.001). Conclusions: Our data confirm that allo-RIC offers a low toxicity profile and a chance for prolonged long-term disease-free survival in MCL, particularly in younger patients.
Introduction
Mantle cell lymphoma (MCL) is considered an incurable disease [Dreyling et al. 2008; Weissenburger and Armitage, 1996] . Allogeneic transplantation offers the opportunity to definitively eradicate the disease through its immunological effect: the graft-versus-lymphoma (GVL) effect [Butcher and Collins, 2005; Jones et al. 1991] . Owing to its high toxicity, high-dose myeloablative conditioning has been limited to young patients without comorbidities [Peniket et al. 2003; McSweeney et al. 2001] . Reduced-intensity conditioning (RIC) regimens have been used in lymphomas trying to reduce the toxicity while preserving the establishment of a significant GVL effect [Rezvani et al. 2008; Vigouroux et al. 2007 ; Morris et al. 2004; Khouri et al. 2001; Nagler et al. 2000] , although the relapse rates appear to be higher than with myeloablative conditioning [Rodriguez et al. 2006 ]. Few homogeneous transplant series have been reported focused on MCL [Maris et al. 2004; Khouri et al. 2001 Khouri et al. , 1999 and these studies suggest that MCL appears to be particularly sensitive to the GVL in comparison to other lymphoma types.
Here we report our experience with an intermediate-intensity conditioning regimen including fludarabine plus melphalan.
Design and methods

Patients
We retrospectively analysed the results of a fludarabine/melphalan-based RIC regimen in Most of the patients reported in this study were included in two prospective multicentre trials evaluating the role of RIC in lymphomas promoted by Grupo Españ ol de Linfomas y Trasplante de Médula Osea (GELTAMO-GETH 00/270 and 02/359). The trials were previously approved by the ethics committees of every centre and all patients received and signed informed consent prior to their inclusion. The RIC consisted of fludarabine 125 or 150 mg/m 2 from day À8 to À4 and melphalan 80 or 140 mg/m 2 on days À3 and À2 (FLU-MEL). Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and short course methotrexate. Four doses of rituximab (375 mg/m 2 ) were added to RIC on days À8, þ1, þ8 and þ15 in eight patients included in the last trial, with the aim of trying to reduce the relapse rate and the incidence of GVHD. Cyclosporine tapering was initiated from day þ50 if mixed chimerism or persistent disease were present, or after day þ90 in any other situation. We focused our analysis on engraftment, toxicities, nonrelapse mortality (NRM), chimerism kinetics, GVHD incidence and severity, response rate, progression-free and overall survival (PFS and OS).
Statistical analysis
Statistical analyses were conducted using the SPSS 16.0 software package (SPSS Inc., Chicago, IL). Estimates of NRM were calculated using cumulative incidence rates, taking into account the competing risk structure. Estimations included 95% confidence intervals (95% CI). All p-values were two sided and considered statistically significant when less than 0.05. The probabilities of OS and PFS were estimated from the time of allo-PBSCT-RIC using KaplanMeier plots and compared using the logrank test.
Results
From 2000 to 2008, 21 MCL patients were transplanted in 7 Spanish centres with a median follow up of 48 months (range: 591 months). Patient and transplant characteristics are described in Table 1 . These patients received a median of two chemotherapy lines, that lead to a complete or partial response (CR or PR) prior to the allo-PBSCT-RIC. All patients engrafted reached neutrophil counts of more than 500/ml on day þ16 (1320) and platelet counts of more than 20,000/ml on day þ12 (832). Early toxicity (before day þ100) included World Health Organization (WHO) grade 23 mucositis in nine patients (43%), febrile neutropenia in seven (33%) and bacterial infections in four (19%). Two patients died before day þ100 (one with herpetic encephalitis on day þ15 and one with steroid-refractory acute GVHD on day þ65). There were two more deaths within the first year, due to chronic GVHD with infectious complications (Escherichia coli sepsis in one case and cytomegalovirus [CMV] enterocolitis and Aspergillus pneumonia in one more), leading to a 1-year and 3-year cumulative incidence of NRM of 19.5% (95% CI: 847%). Complete donor T-cell chimerism was present at day þ30 in 77% of the 17 evaluated patients and in 100% of them at day þ90. No patients received posttransplant donor lymphocyte infusions. Grade IIIV acute GVHD occurred in six patients (30%), including three cases (15%) of grade IIIIV. All of these cases were treated with steroids and cyclosporine, adding thymoglobulin in two grade IIIIV cases. Chronic GVHD appeared in 14/18 patients at risk (78%), being extensive in 7 (39%) and contributed to death in 2 patients. Response rate was evaluated at day þ100: all patients transplanted in CR continued in CR and four out of five transplanted in PR reached CR. Only one patient (transplanted in PR after two treatment lines) relapsed, 6.5 years after allo-PBSCT-RIC. The 5-year estimated PFS and OS were both 80% (95% CI: 6397%) ( Figure 1) . A total of 17 patients remain alive, 16 in continuous CR. Age was found to be the only statistically significant prognostic factor for PFS and OS: patients aged !60 (n ¼ 7) had a 43% OS (95% CI: 779%) versus 100% (95% CI: 74100%) for those younger than 60 years (p < 0.001) ( Figure 2 ). Other factors such as the number of treatment lines previous to allo-PBSCT-RIC, the use of rituximab in the conditioning regimen, the remission status at transplantation, the time to engraftment, achievement of complete T-cell chimerism before day þ100 and the presence of acute or chronic GVHD had no apparent influence on survival, although there was a trend to a favourable outcome with the use of melphalan 80 mg/m 2 instead of 140 mg/m 2 in the conditioning regimen (p ¼ 0.1). The high mortality observed in older patients was due to infections and GVHD, occurring in four out of seven patients: two in first CR after one treatment line, one in CR after three treatment lines and one in PR after four lines of treatment.
Discussion
MCL is usually considered an incurable disease [Dreyling et al. 2008; Weissenburger and Armitage 1996] . Current treatment options include immunochemotherapy with R-CHOP or R-FCM-like regimens [Dreyling et al. 2008] , or more intensive regimens such as R-HyperCVAD alternating with high-dose methotrexate and cytarabine [Romaguera et al. 2005 ], followed or not by autologous PBSCT Vandenberghe et al. 2003] or radioimmunotherapy [Dreyling M et al. 2008 . Recently, the Nordic Lymphoma Group has reported on the use of intensive immunochemotherapy with autologous stem cell support in a large prospective trial (MCL-2) with 6-year OS, event-free survival (EFS) and PFS of 70%, 56% and 66%, respectively, and no relapses occurring after 5 years [Geisler et al. 2008] . Even when employing these highly intensive approaches, a great proportion of patients ultimately relapse. Only allogeneic transplantation, limited to younger patients due to its toxicity, offers the chance for a definitive cure but with a high procedure-related mortality [Hosing et al. 2003; Peniket AJ et al. 2003; Khouri et al. 1999] . RIC regimens attempt to reduce the NRM while preserving the GVL effect of the allogeneic graft. Different RIC regimens have been employed in lymphomas [Rezvani et al. 2008; Vigouroux et al. 2007; Morris et al. 2004; Khouri et al. 2001; Nagler et al. 2000 ], showing promising results in different histologic subgroups, mainly in patients transplanted in remission. Few series focusing on MCL have been reported [Maris et al. 2004; Khouri et al. 2003 ], but their results suggest that MCL would be quite sensitive to the GVL effect. The best conditioning regimen in the nonmyeloablative setting is unknown, with their intensities gradually increasing from the minimum conditioning regimen employed by the Seattle group [Maris et al. 2004] . We chose an intermediate conditioning regimen in order to control the residual disease before the GVL effect developed.
In this report, allo-PBSCT-RIC with FLU-MEL in MCL patients offered an acceptable toxicity profile with high engraftment rate, similar to previous reports of fludarabine-based RIC regimens [Vigouroux et al. 2007; Morris et al. 2004; Khouri et al. 2003 Khouri et al. , 1999 Nagler et al. 2000 ]. The conditioning regimen was well tolerated and the toxic complications (mucositis, febrile neutropenia and infections) observed in our patients were similar to those observed in other RIC transplantation procedures. No differences were observed in the incidence of mucositis or other complications between the patients treated with melphalan 80 mg/m 2 or 140 mg/m 2 in the conditioning regimen. Furthermore, the 1-year NRM (19.5%) was similar or even inferior to that reported by other authors [Maris et al. 2004; Khouri et al. 2003 ], but only 3 out of 21 patients have previously received an autograft.
Acute GVHD was observed in 30% of patients and it was successfully controlled in most of our Therapeutic Advances in Hematology 2 (1) cases, although it did contribute to death in the context of infections in two patients. Chronic GVHD affected a significant proportion of patients (78%), being extensive in almost 40% of them (probably due to early immunosuppression withdrawal, after day þ90 in the absence of GVHD). The very low long-term relapse rate observed (1/21), in the context of a high incidence of chronic GVHD, in our opinion, supports the sensitivity of MCL to a GVL effect.
In our study, the 5-year EFS and OS (both 80%) are remarkable, particularly in this elderly and multitreated group of patients with predominately high-risk disease according to mantle cell lymphoma International Prognostic Index (MIPI). We have not observed any difference in the outcome regarding previously reported favourable independent prognostic factors for both EFS and OS, such as CR (versus PR) disease status at transplant [Corradini et al. 2007; Robinson et al. 2002] , or reaching early (versus late) complete donor chimerism [Bishop et al. 2003 ], probably due to the chemosensitivity of all of our patients that probably introduces a favourable selection bias and the early achievement of complete chimerism in our group of patients. Of course, the limited number of patients included in this study limits the statistical power of our analysis and hampers us from drawing any definite conclusions. However, the homogeneous conditioning regimen used for allo-PBSCT-RIC and the long follow up (median of 4 years) in a well-defined histologic subgroup of MCL patients are factors that enhance the strength of our conclusions. Of note, it should be emphasized that the 5-year OS for the 14 patients younger than 60 years reaches 100% while it is significantly inferior, around 43%, in older patients. Chronic GVHD after RIC in lymphoma patients older than 55 years has been previously reported by our group to be a negative factor for PFS and OS in another series of lymphoma patients [Caballero et al. 2004 ]. This advanced age and comorbidities are important factors to consider when deciding whether to perform a high-risk procedure such as allo-PBSCT-RIC, even in the setting of an incurable disease such MCL.
Conclusion
In conclusion, our long-term results with FLU-MEL as RIC for transplantation in MCL patients suggest that this approach can induce prolonged remissions or cures, with an acceptable toxicity, particularly in patients younger than 60 years.
The durable disease control for the majority of our patients, in the presence of a high incidence of chronic GVHD, suggests the important role played by the GVL effect. These results support the continued use of RIC in young MCL patients in early phases of the disease, but newer approaches are needed for patients older than 60 years. Prospective studies comparing intensified immunochemotherapy and autologous stem cell support versus RIC are urgently needed.
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